Exact Sciences (NASDAQ:EXAS – Get Free Report) and Briacell Therap (NASDAQ:BCTX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Volatility and Risk
Exact Sciences has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Exact Sciences and Briacell Therap, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exact Sciences | 1 | 20 | 2 | 1 | 2.13 |
| Briacell Therap | 1 | 0 | 1 | 0 | 2.00 |
Valuation and Earnings
This table compares Exact Sciences and Briacell Therap”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exact Sciences | $2.76 billion | 7.08 | -$1.03 billion | ($5.32) | -19.24 |
| Briacell Therap | N/A | N/A | -$26.31 million | ($44.05) | -0.10 |
Briacell Therap has lower revenue, but higher earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 1.2% of Exact Sciences shares are owned by company insiders. Comparatively, 5.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Exact Sciences and Briacell Therap’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exact Sciences | -32.01% | 1.67% | 0.70% |
| Briacell Therap | N/A | -275.07% | -188.44% |
Summary
Exact Sciences beats Briacell Therap on 9 of the 14 factors compared between the two stocks.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
